Recombinant Sendai Virus as a Novel HIV Vaccine Vector
Recombinant Sendai Virus as a Novel HIV Vaccine Vector
批准号:
6696129
负责人:
Karen S Slobod
金额:
$22.5万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-01 至 2005-07-31
关键词:
AIDS vaccines B lymphocyte HIV envelope protein T lymphocyte antigen antibody reaction biotechnology humoral immunity inhalation drug administration laboratory mouse laboratory rat live vaccine mucosal immunity parainfluenza virus type 1 recombinant DNA recombinant virus transfection /expression vector vaccine development vector vaccine
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The long-term objective of this project is to prepare and characterize an effective, live virus vaccine candidate for HIV. A successful HIV vaccine should be easily produced, administered and should trigger potent and durable B and T cell responses. The murine parainfluenza type 1 virus (Sendal virus; SV) is a member of the Paramyxovirus family which can be manipulated through reverse genetics to deliver HIV envelope glycoproteins. This murine virus is likely to prove an excellent vaccine vector based on preliminary results from our current human trials examining SV as a vaccine for human parainfluenza virus type 1 and our studies indicating the potent immunogenicity of intranasal SV and SV recombinants (rSV). We further suggest that intranasal administration of SV-based vaccines will prove to be a facile and effective means of priming systemic and mucosal immune responses against HIV. In this focused application we propose the following two aims to meet our objectives of characterizing the immune potential of SV-based HIV vaccines:
Aim 1: To examine mucosal and systemic B cell responses elicited by intransasal recombinant SV expressing HIV envelope protein (rSV-env). Aim 2: To examine CD4 + and CD8 + T cell responses elicited by intransasal rSV-env. It is expected that as a live virus vaccine, rSV-env will elicit strong and durable B and T cell responses, to be evaluated in the two specific aims. Unique attributes of rSV which predict the success of this vaccine vector include the capacity to expand rSV to enormous titer in eggs (an FDA-approved culture system for human vaccines), easy administration by the intranasal route (obviating requirement for sterile syringes and needles and a route capable of inducing mucosal IgA) and the capacity to elicit potent and stable B and T cell responses. Studies described in this application may ultimately identify rSV as an effective intranasal vaccine vehicle useful in the prevention of HIV.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clinical and Primate Paramyxovirus Vaccine Evaluation
-
批准号:6735428
-
项目类别:
-
资助金额:$21.65万
-
财政年份:2003
-
负责人:Karen S Slobod
-
依托单位:
Recombinant Sendai Virus as a Novel HIV Vaccine Vector
-
批准号:6776965
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2003
-
负责人:Karen S Slobod
-
依托单位:
CLINICAL EVALUATION OF A MULTI-ENVELOPE AIDS VACCINE
-
批准号:6320777
-
项目类别:
-
资助金额:$20.79万
-
财政年份:2000
-
负责人:Karen S Slobod
-
依托单位:
CLINICAL EVALUATION OF A MULTI-ENVELOPE AIDS VACCINE
-
批准号:6167470
-
项目类别:
-
资助金额:$20.79万
-
财政年份:1999
-
负责人:Karen S Slobod
-
依托单位:
TREATMENT OF EBV LYMPHOMA BY INDUCTION OF EPISOMAL LOSS
-
批准号:2642945
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1997
-
负责人:Karen S Slobod
-
依托单位:
Clinical and Primate Paramyxovirus Vaccine Evaluation
-
批准号:7231990
-
项目类别:
-
资助金额:$21.94万
-
财政年份:--
-
负责人:Karen S Slobod
-
依托单位:
Clinical and Primate Paramyxovirus Vaccine Evaluation
-
批准号:7068665
-
项目类别:
-
资助金额:$21.67万
-
财政年份:--
-
负责人:Karen S Slobod
-
依托单位:
Clinical and Primate Paramyxovirus Vaccine Evaluation
-
批准号:7433805
-
项目类别:
-
资助金额:$20.22万
-
财政年份:--
-
负责人:Karen S Slobod
-
依托单位:
Clinical and Primate Paramyxovirus Vaccine Evaluation
-
批准号:7624655
-
项目类别:
-
资助金额:$23.4万
-
财政年份:--
-
负责人:Karen S Slobod
-
依托单位:
海外基金